Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher Corporation (NYSE: DHR) announced on September 14, 2022, that its President and CEO, Rainer M. Blair, will discuss the anticipated strong performance of the company in the third quarter 2022 during an investor meeting. The company expects core revenue growth to exceed previous guidance due to increased Cepheid respiratory testing revenue, projected to surpass $500 million compared to the earlier estimate of $325 million. Base business core revenue growth is expected in the high single-digit range.
Danaher Corporation (NYSE: DHR) announced plans to separate its Environmental & Applied Solutions (EAS) segment into an independent, publicly traded entity. This separation, expected to be tax-free for shareholders and completed in Q4 2023, will focus on Danaher's Water Quality and Product Identification businesses. EAS, projected to generate approximately $4.7 billion in revenue in 2021, aims for enhanced investment opportunities with a resilient business model and a dedicated leadership team. Jennifer Honeycutt will serve as CEO of EAS post-separation.
On September 13, 2022, Danaher Corporation (NYSE: DHR) declared a quarterly cash dividend of $0.25 per share for common stock, payable on October 28, 2022, to shareholders of record on September 30, 2022. Additionally, a dividend of $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock was announced, payable on October 15, 2022, also to shareholders recorded by September 30, 2022.
Danaher Corporation (NYSE: DHR) will host a live video webcast of its Bioprocessing Investor and Analyst Meeting on September 15, 2022, at 12:00 p.m. ET. The event will take place at the Cytiva facility in Marlborough, Massachusetts, featuring President & CEO Rainer M. Blair and VP Emmanuel Ligner. Interested parties can access the webcast and presentation slides in the
On July 25, 2022, Beckman Coulter announced a partnership with Massachusetts General Hospital to validate the Monocyte Distribution Width (MDW) biomarker for identifying severe pediatric infections. Funded by BARDA, the multi-center trial focuses on children under 15 with high fevers, aiming to enhance early detection of those at risk for hospitalization. This initiative leverages MDW's existing FDA clearance for adult sepsis, expanding its clinical utility in emergency departments, potentially allowing for quicker, informed treatment decisions without unnecessary testing.
Danaher Corporation (NYSE: DHR) reported its Q2 2022 results, showing net earnings of $1.7 billion or $2.25 per diluted share, a 1.5% decrease year-over-year.
However, non-GAAP adjusted diluted net earnings increased by 12% to $2.76 per share. Revenues rose 7.5% to $7.8 billion, with a core revenue growth of 9.5%. Operating cash flow stood at $2.0 billion, while non-GAAP free cash flow reached $1.7 billion. For Q3, the company expects high-single digit growth in core revenue.
Nordson Corporation (Nasdaq: NDSN) announced a strategic realignment of its business segments effective August 1, 2022. The new structure includes three segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS). This change aims to enhance visibility in growing medical and electronics platforms. In fiscal 2021, IPS generated approximately $1.2 billion, MFS $0.6 billion, and ATS $0.5 billion in revenues. The company remains focused on top-tier growth with a commitment to innovative solutions across diverse end markets.
Danaher Corporation (NYSE: DHR) has appointed Feroz Dewan to its Board of Directors, increasing the board size from thirteen to fourteen members. Dewan, currently CEO of Arena Holdings Management, brings extensive experience from Tiger Global Management and Silver Lake Partners. His appointment aims to enhance Danaher's financial acumen and technology expertise, as noted by Chairman Steven M. Rales. Danaher is committed to innovation in healthcare, environmental and applied markets, supported by a team of approximately 80,000 associates.
Danaher Corporation (NYSE: DHR) will host a webcast for its second quarter 2022 earnings conference call on July 21, 2022, starting at 8:00 a.m. ET. The call, anticipating a duration of approximately one hour, will be accessible via the Investors section of Danaher's website. A replay will be available post-call until August 4, 2022. The earnings press release, along with slide presentations, will be posted online from 6:00 a.m. ET on the day of the call.
SciEX, part of Danaher Corporation (NYSE:DHR), has launched Zeno SWATH DIA, enhancing biomarker discovery through improved sensitivity and speed. The new system can quantify up to 2x the proteins in cell and plasma samples, significantly boosting clinical test development. Researchers can achieve large population-scale proteomic studies in weeks with 5-minute run-times, optimizing costs and sample usage. This advancement is expected to drive new therapies and precision medicine, reflecting a significant step forward in translational OMICS research.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
